Q2 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript
Key Points
- Xeris Biopharma Holdings Inc (XERS) reported a 49% increase in total revenue, reaching a quarterly record of $71.5 million.
- The company's commercial product portfolio grew by 46%, driven by increased patient demand across all three products: Recorlev, Gvoke, and Keveyis.
- Recorlev showed impressive growth with a 136% year-over-year increase in revenue, solidifying its position in the Hypercortisolemia and Cushing's syndrome market.
- Xeris Biopharma Holdings Inc (XERS) raised its full-year revenue guidance to $280 million to $290 million, reflecting a positive trajectory and confidence in product demand.
- The company achieved a positive adjusted EBITDA of $12.5 million, demonstrating strong operational efficiency and the ability to translate top-line performance into bottom-line results.
- Gross margin slightly decreased to 82% due to non-routine expenses associated with Gvoke capacity expansion efforts.
- Research and development expenses increased by $2.2 million compared to the previous year, reflecting continued investment in the pipeline.
- Selling, general, and administrative expenses rose by 11% year-over-year, primarily due to the Recorlev commercial expansion and personnel-related costs.
- The company anticipates a modest year-over-year increase in total SG&A and R&D expenses, which could impact profitability.
- There is potential competition in the Hypercortisolism market with a new drug expected to launch by the end of the year, which could affect Recorlev's market dynamics.
Hello everyone, and thank you for joining the Xeris Biopharma second quarter 2025 earnings conference call.
(Operator Instructions)
I'll now hand over to your host, Allison Wey, Senior Vice President of Investor Relations and Corporate Communications to begin. Please go ahead, Allison.
Thank you, Sammy. Good morning everyone and thank you for joining our call today. I'm joined with John Shannon, our CEO, and Steve Pieper, our CFO. Earlier this morning, we issued a press release with our detailed results, which can be found on our website. After our prepared remarks, we will open the lines for questions.
Before we begin, I'd like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, projects, and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
